retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Mounjaro: and Diabetes Retatrutide vs. Tirzepatide: The Next-Gen
Description
doi: 10.1055/s-0043-120439
Solving the puzzle of long Covid
First, the expression of GLP-1R remains controversial in many types of cells and tissues due to the lack of specific antibody against GLP-1R
In a head-to-head study (SURPASS-2), Mounjaro topped Ozempic (1 mg semaglutide), showing it was more effective in helping patients keep their blood sugar levels in check and lose weight
